[Summary] A high-tech pharmaceutical enterprise engaged in the full-industry-cha
Jiangsu Wekaier Pharmaceutical Technology Co., Ltd. (referred to as "Wekaier") was co-founded in 2010 by professors from China Pharmaceutical University and overseas returnees. Wekaier has invested 200 million yuan to build a 21,000-square-meter R&D center located in the Nanjing Jiangbei New Area High-Tech Biomedical Valley. The company focuses on independent R&D of Class 1 innovative drugs, covering the entire drug lifecycle from early screening and discovery, to non-clinical research and pharmaceutical research, and then to clinical research and development. Wekaier currently has nearly 900 employees, with technical staff accounting for over 85%. The core team has more than 10 years of rich experience in new drug R&D and possesses 9 high-end core technology platforms: AI molecular generation technology platform, new drug screening technology platform, chiral drug synthesis technology platform, continuous flow technology platform, bioenzyme chemical technology platform, chiral drug analysis technology platform, preparative separation technology platform, crystal form and salt form R&D technology platform, and new drug formulation technology platform, fully meeting the R&D needs of high-tech-barrier new drugs. In 2021, its wholly-owned subsidiary "Nanjing Wekaier Biomedical Technology Co., Ltd." was spun off to independently operate CRO/CDMO businesses. Adhering to an international perspective, Wekaier deeply focuses on the full industry chain and full lifecycle R&D and production services of chemical drugs, striving to build a one-stop "Chemistry + Pharmacy + Medicine" CRO/CDMO service platform. It accelerates drug R&D and is committed to providing innovative drug and generic drug CMC, clinical, and regulatory (CRO) services, as well as innovative drug contract research and manufacturing (CDMO) services, and the production and sales of specialty innovative drugs, advanced pharmaceutical intermediates, and impurities, for global pharmaceutical companies and new drug R&D institutions. In 2023, its subordinate production base located in Yicheng Chemical Industrial Park, Xiangyang, Hubei, covering an area of 130 mu - Hubei Tianshu Pharmaceutical Co., Ltd. (referred to as "Tianshu Pharmaceutical") - was officially put into operation. To date, Wekaier has provided full-industry-chain, full-lifecycle CRO/CDMO services to more than 300 well-known domestic and international biomedical enterprises and research institutions, assisted clients in obtaining more than 20 drug registration approvals, more than 10 clinical trial approvals, and over 50 routine registration applications, and supplied over 3,000 types of supporting intermediates, impurities, and APIs. Adhering to the corporate culture of "Focus, Rigor, and Excellence," Wekaier is committed to building a domestic first-class and internationally renowned chemical drug full-industry-chain, full-lifecycle R&D and production service platform.
What does Jiangsu Wekaier Pharmaceutical Technology Co., Ltd. require? Who is Jiangsu Wekaier hiring? Jiangsu Wekaier recruitment: 经营管理类占比最多占39.6%，其次是生物/制药/化工/环保类占36%. What education can get in at Jiangsu Wekaier? 本科占比最多占64%，其次是大专占27.1%. High education required at Jiangsu Wekaier? 硕士占6.3%，博士占1.5%. Work experience required at Jiangsu Wekaier? 不限占比最多占30.1%，其次是3-5年占27.7%. Where are the job locations at Jiangsu Wekaier? 南京占比最多占59.2%，其次是襄阳占26.2%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
